Becton Dickinson and Co. (NYSE:BDX) is a leading global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. The company operates through three segments: BD Medical, BD Life Sciences, and BD Interventional, competing with other major players in the healthcare sector, such as Medtronic and Johnson & Johnson.
On February 10, 2026, BDX executed a stock split with a ratio of 125 for 159, a strategic move often aimed at making shares more affordable to a broader range of investors. Following the split, BDX reported first-quarter 2026 adjusted earnings of $2.91 per share, surpassing the consensus estimate of $2.81. The company's sales reached $5.25 billion, slightly exceeding the expected $5.15 billion.
BDX is undergoing significant changes, including the separation of its Biosciences and Diagnostic Solutions businesses and a combination with Waters Corporation. Despite these changes, the company has lowered its fiscal 2026 adjusted earnings guidance from a range of $14.75-$15.05 per share to $12.35-$12.65 per share, compared to the consensus of $14.72. RBC Capital Markets has reduced its price forecast for BDX from $210 to $172, describing fiscal 2026 as a "transition year."
The stock for BDX is currently priced at $180.62, reflecting an increase of 5.21% or $8.94. During the trading day, the stock has fluctuated between a low of $170.67 and a high of $181.98. Over the past year, BDX has reached a high of $185.02 and a low of $127.59. The company's market capitalization stands at approximately $51.44 billion, with a trading volume of 4,441,319 shares on the NYSE.
